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Background: Co-morbidities are common in chronic obstructive pulmonary disease (COPD). We assessed the
contribution of common co-morbidities on health related quality of life (HRQoL) among COPD patients.
Methods: Using both generic (15D) and respiratory-specific (AQ20) instruments, HRQoL was assessed in a hospital
based COPD population (N = 739, 64% males, mean age 64 years, SD 7 years) in this observational study with inferential
analysis. The prevalence of their co-morbidities was compared with those of 5000 population controls. The patients
represented all severity stages of COPD and the patterns of common concomitant disorders differed between patients.
Results: Co-morbidities such as psychiatric conditions, alcohol abuse, cardiovascular diseases, and diabetes were more
common among COPD patients than in age and gender matched controls. Psychiatric conditions and alcohol abuse
were the strongest determinants of HRQoL in COPD and could be detected by both 15D (Odds Ratio 4.7 and 2.3
respectively) and AQ20 (OR 2.0 and 3.0) instruments. Compared to respiratory specific AQ20, generic 15D was more sensitive
to the effects of comorbidities while AQ20 was slightly more sensitive for the low FEV1. FEV1 was a strong determinant of
HRQoL only at more severe stages of disease (FEV1 < 40% of predicted). Poor HRQoL also predicted death during the
next five years.
Conclusions: The results suggest that co-morbidities may impair HRQoL at an early stage of the disease, while
bronchial obstruction becomes a significant determinant of HRQoL only in severe COPD.
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Chronic obstructive pulmonary disease (COPD) is glo-
bally one of the leading causes of morbidity, disability,
and mortality according to World Health Organization
(http://www.who.int/respiratory/copd/en/). For decades,
COPD was considered simply as a disease with progres-
sive airflow limitation. Lately it has become obvious that
COPD patients suffer simultaneously from several
extra-pulmonary diseases such as cardiovascular dis-
eases, diabetes, osteoporosis, musculoskeletal dysfunc-
tion, chronic kidney and heart failure, anxiety, depression,* Correspondence: jukka.koskela@helsinki.fi
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unless otherwise stated.and addiction diseases [1-5]. In several population studies
both increased morbidity and mortality are associated
with lung function impairment [6-13]. Furthermore, co-
morbidities have additional impact on health, for example
the response to treatment received for coronary artery dis-
ease is worse in patients with co-existing COPD [14,15].
The underlying causes of multi-morbidity in COPD are
still poorly understood. The co-occurrence of the diseases
may appear simply due to patients’ aging, or due to shared
risk factors or etiological pathways. The latter is compat-
ible with the hypothesis that COPD sustains systemic in-
flammation in the body [4].
Spirometry alone is not enough in clinical practice to pre-
dict the future outcome of COPD as for instance exacerba-
tion rates and co-morbidity may contribute as well [16].
This has initiated studies to develop a multidimensionalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of COPD than FEV1 alone. Health related quality of life
(HRQoL) has become one of the components of interest.
So far our experience on HRQoL in COPD has mainly
emerged from randomised clinical trials in which HRQoL
is frequently evaluated as a secondary end point [17,18].
Contrary to clinical practice, the severity of COPD is often
restricted and patients with severe co-occurring diseases
are under-represented or even excluded. Traditionally, the
number of female patients has been limited in clinical trials
as well, while it is known that this affects the prevalence of
co-morbidities [19] and treatment decisions [20]. Therefore,
determining the effect of co-morbidities and gender on
HRQoL has become increasingly important also in real
world observational studies. There is also a need for
the development of programs that enhance supportive
care for patients with severe COPD [21]. This is par-
ticularly important since HRQoL may offer a good
outcome-measure for holistic interventional studies
that take into account patient’s physical, psychological,
social and spiritual well-being.
In the present study we aim to estimate the contribu-
tion of common co-morbidities on self-reported HRQoL
among COPD patients by using two questionnaires: the
AQ20 focusing on respiratory health [22] and the 15D
focusing on generic health [23]. Both questionnaires are
simple and short, and can be used easily in clinical prac-
tice with high response and completion rates [24,25].
AQ20 has discriminative properties and responsiveness
comparable to more complex questionnaires such as
SGRQ [24], and 15D and AQ20 have convergent validity
to measure HRQoL in COPD [25]. We also studied the
association between HRQoL and the 5-year-mortality.
Methods
Subjects
Hospital Discharge Registries were used to identify all
patients with COPD who had visited the Pulmonary
Clinics of the Helsinki and Turku University Hospitals
during the years 1995–2006. The databases were
screened by ICD10 code J44.8 and contained all patients
between 18 to 75 years of age. The upper level was se-
lected due to our study design, which included a 10-year
follow-up. All identified patients were invited to the
study without further selection. The recruitment was
done through a two-phase mailing campaign, through
which altogether 844 patients participated the study
[26], after which their diagnosis was carefully assessed
going through the medical records by a pulmonologist.
This resulted in 739 confirmed COPD patients (clinical
symptoms and airway obstruction according GOLD) with
smoking related disease. The enrolment occurred during
the years 2005–2007. All the participants gave informed
consent to collect, merge, and analyse their comprehensivemedical history from all the healthcare providers who had
treated them during the past 5–10 years. Participants of the
Health2000 survey (N = 5000) were used as age and gender
matched population controls to avoid biased inferences.
Their diagnostic data had been gathered from the hospital
discharge registries (http://www.terveys2000.fi/indexe.html).
Assessment of HRQoL
The HRQoL was assessed using the self-administered Air-
ways Questionnaire 20 [27] and 15D (http://www.15d-
instrument.net/15D). All participants filled in both
questionnaires during the research visit without any guid-
ance from the research personnel. The AQ20 questionnaire
was used as the disease-specific instrument of HRQoL. This
questionnaire was developed in 1998 for use in asthma [27]
and COPD [22,28]. The AQ20 is a uni-dimensional meas-
ure containing 20 items with “yes” responses are scored as
1, and “no” and “not applicable” are scored as 0. The scores
of 1 are summed up to obtain the AQ20 summary score,
which ranges from 0 to 20, a score of zero indicating no
respiratory symptoms or worries about the disease. The
15D–instrument [29] is a generic, multidimensional, stan-
dardized, self-administered evaluative tool of HRQoL that
can be used primarily as a single index measure, but also
as a profile measure. It describes the health status, with 15
dimensions, namely: mobility, vision, hearing, breathing,
sleeping, eating, speech, excretion, usual activities, mental
function, discomfort and symptoms, depression, distress,
vitality, and sexual activity. Each dimension comprises one
question on a 5-point scale. A single index score is
obtained by incorporating population-based prefer-
ence weights to the 15 dimensions. The maximum
score is 1 (no problems on any dimension) and the
minimum score is 0 (being dead). The 15D instru-
ment has good test–retest reliability, construct valid-
ity, and discriminatory power in general populations
[23] and has been validated for use in COPD [30,31].
All participants returned the questionnaire at the recruit-
ment session. There was no missing data for AQ20, for 15D
eight patients did not finish the questionnaire completely
and this data was omitted from analysis. Recall bias was
not assessed in this study.
Physiological measurements and co-morbid conditions
All hospitals, health care centres, and other outpatient
clinics that had treated the patients were contacted to
archive a complete medical history for each participant.
The patients’ social security number was used to combine
the data from different sources. Source data with personal
identifiers were managed and stored in the Clinical Re-
search Centres administered by the Helsinki and Turku
University Central Hospitals. The results of flow-volume
spirometry including bronchodilatation tests nearest to
index date, diffusion capacity, ECGs at rest, weight, height
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ence values used for FEV1 and FVC in Finnish clinical
practice were validated in large Finnish population sam-
ples consisting of both genders and a wide range of age
groups [32]. All the given diagnoses stated in the medical
records were carefully evaluated; especially concerning the
time of onset and certainty of the diagnosis was deter-
mined. Category ‘coronary disease’ included the patients
who have had a myocardial infarction, acute coronary ar-
tery syndrome, or angina pectoris diagnosed by an intern-
ist or cardiologist. ‘Cerebrovascular diseases’ included
patients with strokes and transient ischemic attacks diag-
nosed by a neurologist. ‘Cardiovascular diseases’ consisted
of patients having one of the following diseases: coronary,
cerebrovascular disease, or peripheral artery occlusive dis-
ease. Chronic atrial fibrillation was confirmed by ECG
recordings. Category ‘diabetes’ includes patients with
the type 1 and 2 disease. Chronic alcoholism, alcohol
use disorder, and treatment of alcohol-use related dis-
orders were categorized as ‘alcohol abuse’. A wide
range of psychotic disorders and long lasting clinical
depression, and anxiety that needed regular medication
were categorized as ‘Psychiatric condition’. Category ‘can-
cer’ included all malignant solid tumours and malignant
haematological diseases. The prevalence of the common
co-existing diseases were compared with an age and gen-
der matched control population from a Finnish population
survey (Health 2000, N = 5000) [33]. Diffusing capacity
and ECG were available from a limited number of the pa-
tients and therefore excluded from the multivariate re-
gression analyses (Table 1 and Additional file 1: Table S3).
The modified Medical Research Council (mMRC) dyspnoea
scale was used to measure subjective breathlessness [34].
The Coordinating Ethics Committee of the Helsinki
and Uusimaa Hospital District approved the study ap-
proach, and the permission to conduct this research was
granted by the Helsinki and Turku University Hospitals.
All the clinical studies, sample collection and storage,
and data gathering processes were done according to the
standardised operational procedures (SOPs), the training
of the study personnel has been documented and done
according to good clinical practice. Clinical study processes
have been monitored after enrolment and after each
annual follow-up contact with the study subject.
Statistical analysis
Analyses were performed by the statistical software
packages SPSS (IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY: IBM
Corp) and R Statistical Software (R Development Core
Team (2008), R version 2.15, http://www.R-project.org).
Correlations of 15D and AQ20 scores with lung func-
tion measurements were analysed using the Spearman
correlation coefficient. Both HRQoL scores were analysedas continuous and as categorised variables. Analysis of
continuous endpoints enables inferences throughout the
scale of HRQoL, while categorised endpoints only compare
differences between two groups. Thus parallel analysis of
categorised and continuous endpoints was used as sup-
portive approach to confirm congruent results. Linear re-
gression was used to determine clinically valid attributes
potentially affecting HRQoL and to compare their relative
importance. Regression coefficient B is the change in
HRQoL when dependent variable changes with one unit.
To quantify the effect of a particular dependent variable
we determined standardized regression coefficient β,
which is a modification of B. The effect is standardized
from −1 to 1 allowing solid comparison between the
variables. Differences in means of FEV1 % of predicted
were determined using ANOVA combined with Tukey's
Honestly Significant Difference.
The 10.0% (in 15D) and 12.4% (closest discrete value
to 10% in AQ20) of patients having the lowest HRQoL
score formed the low-HRQoL subgroup. Logistic
backwards-stepwise regression was used to determine
the independent risk factors for low HRQoL. All covari-
ates presented as crude ORs (Tables 1 and 2) were in-
cluded into backwards-stepwise logistic regression to
construct a multivariate model defining independent risk
factors for poor HRQoL. The model constructed for
poor 15D was then used to assess its performance in
predicting 5-year mortality by determining Receiver Op-
erating Characteristic (ROC) and Area Under the Curve
(AUC). The Minimal Clinically Important Difference
(MCID) in 15D total score is 0.03 [35]. Analyses were
done separately for both 15D (Table 2) and AQ20
(Table 1).
Results
Study subjects
A total of 739 eligible patients (64% male, mean age 64
± SD 7 years, mean pack years 51 ± SD 20) with COPD
attended the study. The patients were identified through
a two-phase mailing campaign, which was directed to all
elderly asthma, and COPD patients who had visited the
University Hospital of Helsinki and Turku years 1995–
2006 [26]. The diagnosis was made on average 5.5 years
before the enrolment. The severity of the disease was de-
termined by the latest flow volume spirometry, which
was performed within two years before the recruitment.
According to the GOLD criteria [36], the majority of the
patients belonged to the stages 2–3, moderate to severe
COPD.
Even though women had slightly better lung function
(mean FEV1 55 vs. 61% of predicted, p < 0.001), they re-
ported higher scores for several questions related to re-
spiratory symptoms and the mean AQ20 summary score
was significantly higher among women than men (7.9 vs. 8.8
Table 1 Risk factors for low HRQoL (AQ20 summary score ≥14) based on univariate and backwards-stepwise
multivariate regression analysis
Patient characteristics N of patients
analyzed
% patients with
poor HRQoL
Crude OR 95% CI P-value Adjusted OR 95% CI P-value
Gender
Male 422 10.8 1.00
Female 225 15.4 1.51 0.97-2.35 NS 2.11 1.27-3.51 0.004
Age at recruitment
<60 years 215 13.5 1.00
61–68 years 274 14.2 1.06 0.64-1.79 NS
>69 years 250 9.6 0.68 0.38-1.21 NS
FEV1 baseline % of predicted
>80 95 9.5 1.00
65–80 185 4.9 0.50 0.17-1.43 NS 0.54 0.18-1.63 0.27
40–64 323 13.3 1.47 0.63-3.43 NS 2.48 0.99-5.95 0.05
<40 136 22.9 2.84 1.19-6.79 0.02 5.17 2.03-13.17 0.001
Smoking cessation succeed
Yes 358 11.2 1.00
No 281 14.2 1.32 0.83-2.11 NS
BMI units
<19 33 34.3 - - -
19–25 251 4.5 1.00
>25-30 275 37.6 0.64 0.37-1.07 NS
>30 173 23.6 0.95 0.54-1.64 NS
Diabetes
No 628 11.9 1.00
Yes 111 15.3 1.33 0.75-2.36 NS
Cardiovascular Disease1
No 532 13.3 1.00
Yes 207 10.1 0.73 0.44-1.23 NS
Hypertension
No 439 12.3 1.00
Yes 300 12.7 1.03 0.66-1.61 NS
Atrial Fibrillation −2
No 474 14.1 1.00
Yes 31 29.0 2.49 1.10-5.63 0.03
Diffusing capacity
Normal 221 11.8 1.00
Mild/moderately decrease 89 11.2 0.95 0.44-2.06 NS
Severe decrease 103 16.5 1.48 0.77-2.87 NS
Cancer
No 695 12.4 1.00
Yes 44 13.6 1.12 0.46-2.72 NS
Psychiatric conditions
No 493 9.9 1.00
Yes 240 17.1 1.87 1.19-2.92 0.006 1.99 1.21-3.29 0.007
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Table 1 Risk factors for low HRQoL (AQ20 summary score ≥14) based on univariate and backwards-stepwise
multivariate regression analysis (Continued)
Alcohol abuse
No 629 10.5 1.00
Yes 110 23.6 2.64 1.59-4.39 <0.001 3.02 1.65-5.51 0.001
Odd Ratios with P values ≤0.05 are shown in bold.
1coronary, cerebrovascular, or peripheral artery disease, 2due to small number of tested patients not included to the multivariate analysis.
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score did not differ (0.79 for both sexes). Women, how-
ever, reported more difficulties with sleep, depression,
and distress than men. Men suffered more frequently
from impairment of sexual performance than women
(Additional file 1: Table S1).
Co-morbidities in the cohort
Common co-morbidities of the COPD patients were
evaluated from the medical records (Table 3). Cardiovas-
cular diseases, diabetes, and chronic psychiatric condi-
tions were more prevalent in the COPD cohort than
among the gender and age matched Finnish controls.
The prevalence of co-occurrence of the chronic medical
conditions was comparable in males and females, no co-
morbidities 27.9% vs. 26.3%, 1 co-morbidity 31.5 vs. 31.9%,
2 co-morbidities 21.4% vs. 26.3%, 3 co-morbidities 14.6%
vs. 11.7% and ≥4 co-morbidities 4.7% vs. 3.8% respectively.
The number of chronic conditions did not significantly as-
sociate with FEV1 levels.
Lung function and co-morbidities in relation to
HRQoL scores
Both FEV1 and diffusing capacity correlated with the
HRQoL scores weakly or moderately, FEV1 slightly
stronger than diffusing capacity and both lung function
measurement slightly stronger to AQ20 than 15D
(Table 4). The strongest correlation was found between
the two HRQoL instruments (r = −0.69). The lung func-
tion measures (FEV1 and DLCOcVA) were also moder-
ately correlated with each other (r = 0.35).
Only a very small proportion of variance (adjusted R2
3.5%) found in the 15D total score was explained by FEV1
and diffusion capacity alone. When co-morbidities were
added into the model, psychiatric conditions, FEV1, alco-
hol abuse, diabetes, cardiovascular diseases, and hyperten-
sion were significant determinants of the total 15D scores.
Psychiatric conditions (p ≤ 0.001) and FEV1 (p ≤ 0.001)
had the greatest effect (β > 0.2). Alcohol abuse (p ≤ 0.001),
cardiovascular diseases (p = 0.006), and diabetes (p = 0.007)
had β-values in the range of 0.1 – 0.2 while hypertension
(p = 0.04) had the smallest β (0.08). After performing
stepwise regression, explained variance in 15D was in-
creased considerably from 3.5% to 17.6%.
Correspondingly for AQ20, the greatest effect was
found for FEV1 (β = 0.34, p < 0.001), while psychiatricconditions (p ≤ 0.001), female gender (p ≤ 0.001), alcohol
abuse (p = 0.002) all had β-values in the range of 0.1 –
0.2, and hypertension had the smallest effect (β <0.1, p =
0.008). The model including the comorbidities explained
15.5% of the AQ20 summary score, while FEV1 and diffu-
sion capacity alone explained only 6.9% of the variation.
Clinical variables explaining low HRQoL
The mean 15D total score in the cohort was 0.79 (SD
0.11). Patients with the lowest 10% of the 15D score (N =
79/731, 9.6% of men and 11.1% of women) formed the
low 15D category (total score ≤0.65, Table 2). Diabetes
(OR 2.1, 95% CI 1.1-4.2, p = 0.03), psychiatric conditions
and alcohol abuse (OR 2.3, 95% CI 1.2-4.5, p = 0.007), were
independently associated with a low 15D score. The great-
est risk of a low 15D score (OR 4.7, 95% CI 2.6-8.4, p ≤
0.001) was shown among COPD patients with psychiatric
conditions. A low 15D score was significantly related to
airway obstruction only when the patients’ FEV1 was
<40% of predicted. The OR of low 15D score was then
three-fold compared to patients with FEV1 > 80% (95% CI
1.1-8.6, p = 0.03).
The mean AQ20 summary score in the cohort was
8.25 (SD = 5.03). The lowest 12.4% of AQ20 (summary
score >14, N = 92/739, 12.1% of men and 18.2% of
women) was associated with borderline significance to
moderate airway obstruction (OR 2.5, 95% CI 1.0-6.0,
p = 0.05, when FEV1 64-40% of predicted) and signifi-
cantly to severe airway obstruction (OR 5.2, 95% CI 2.0-
13.2, p ≤ 0.001, when FEV1 < 40%). Alcohol abuse (OR
3.0, 95% CI 1.7-5.5, p ≤ 0.001) and psychiatric conditions
(OR 2.0, 95% CI 1.2-3.3, p = 0.007) were the significant
co-morbidities associated with poor AQ20 alongside
with female gender (OR 2.1, 95% CI 1.3-3.5, p = 0.004).
Contrary to 15D, cardiovascular diseases and diabetes
remained non-significant predictors for poor AQ20
score (Table 1). Thirty-three patients were categorised
having low HRQoL by both questionnaires.
The mMRC dyspnoea scale did not remain significant
in any of the models after stepwise model selection.
Mortality and HRQoL
In order to study the importance of the identified risk
factors of low generic HRQoL, the same variables were
used in a 5-year mortality model (Ntotal = 670, Ndead = 105)
(Additional file 1: Table S3). FEV1 < 40% of predicted was
Table 2 Risk factors for a low score on 15D (total score ≤0.65) based on univariate and backwards stepwise
multivariate regression analysis
Patient characteristics N of patients analyzed % patients with
poor HRQoL
Crude OR 95% CI P-value Adjusted OR 95% CI P-value
Gender
Male 470 9.6 1.00
Female 261 11.1 1.18 0.72-1.93 NS
Age at recruitment
<60 years 214 9.8 1.00
61–68 years 269 10.4 1.97 0.59-1.94 NS
>69 years 248 10.1 1.03 0.56-1.90 NS
FEV1 baseline % of predicted
>80 94 8.2 1.00 1.00
65–80 184 7.5 0.91 0.33-1.39 NS 1.02 0.35-3.01 NS
40–64 318 9.8 1.21 0.53-1.88 NS 1.41 0.52-3.80 NS
<40 135 16.5 2.21 0.86-5.71 0.100 3.08 1.10-8.63 0.03
Smoking cessation succeed
Yes 355 7.9 1.00
No 278 12.6 1.68 1.00-2.84 0.05
BMI units
<19 32 9.3 0.65 0.15-2.91 NS
19–25 248 6.2 1.00
>25-30 272 9.2 0.99 0.55-1.79 NS
>30 172 14.0 1.59 0.86-2.92 NS
Diabetes
No 620 8.4 1.00 1.00
Yes 111 19.8 2.70 1.56-4.66 <0.001 2.12 1.07-4.22 0.03
Cardiovascular Disease1
No 526 9.1 1.00 1.00
Yes 205 12.7 1.45 0.87-2.40 NS 1.69 0.93-3.07 0.09
Hypertension
No 434 9.4 1.00
Yes 297 11.1 1.20 0.74-1.94 NS
Atrial Fibrillation
No 468 11.1 1.00 −2
Yes 30 23.3 2.44 1.00-5.95 0.05
Diffusing capacity
Normal 220 10.0 1.00
Mild/Moderately decrease 87 13.8 1.44 0.68-3.05 NS
Severe decrease 102 11.8 1.20 0.57-2.53 NS
Cancer
No 687 10.0 1.00
Yes 44 11.4 1.15 0.44-3.01 NS
Psychiatric conditions
No 488 5.9 1.00 1.00
Yes 237 18.1 3.51 2.13-5.78 <0.001 4.65 2.57-8.40 <0.001
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Table 2 Risk factors for a low score on 15D (total score ≤0.65) based on univariate and backwards stepwise
multivariate regression analysis (Continued)
Alcohol abuse
No 621 8.4 1.00 1.00
Yes 110 20.0 2.74 1.58-4.73 <0.001 2.33 1.21-4.49 0.007
Odd Ratios with P values ≤0.05 are shown in bold.
1coronary, cerebrovascular, or peripheral artery disease, 2due to small number of tested patients not included to the multivariate analysis.
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20.6, p ≤ 0.001) for mortality. Alcohol abuse (OR 2.15,
95% CI 1.19 - 3.88, p = 0.01) and cardiovascular diseases
(OR 1.71, 95% CI 1.06 - 2.73, p = 0.03) were also signifi-
cant risk predictors, while diabetes and psychiatric con-
ditions remained non-significant. The model showed a
substantial prognostic value of mortality (AUC = 0.70).
Both HRQoL scores were compromised among the pa-
tients who died compared to those who lived throughout
the follow-up period (for 15D score 0.75 vs. 0.80, p ≤ 0.001
and for AQ20 score 9.82 vs. 7.99, p ≤ 0.001).
Discussion
The present patient cohort was hospital based represent-
ing all severity stages of the disease [26]. To analyse pa-
tients’ airway specific and generic HRQol we used two
questionnaires. Both questionnaires are validated, well
correlated and short enough to be integrated in clinical
practise [25]. Our results show that cardiovascular dis-
eases, diabetes, alcohol abuse, and different psychiatric
diseases were more frequent in COPD patients than in
controls. Like in previous reports, neither a particular
co-morbidity nor the total number of co-morbidities
correlated to the severity of airway obstruction [37].
However, co-morbidities were the most important determi-
nants of HRQoL in subjects with mild and moderate severe
obstruction. Only the presence of severe obstruction
(FEV1 < 40%) was a significant contributor of HRQoL.
Using the multivariate regression models, we found that
co-morbidities were associated both with general andTable 3 Prevalence of co-morbidities in the COPD cohort com
population survey
Chronic disease COPD cohort N = 739
Men % Women %
Hypertension 41 40
Coronary disease 27 12
Cerebrovascular disease 9 5
Peripheral artery disease 6 2
Diabetes 18 11
Alcohol abuse 18 9
Chronic psychiatric conditions 26 45
Cancer 6 6
1stroke including also intracerebral and subarachnoidal hemorrhage.respiratory specific HRQoL, the strongest effects being ob-
served for psychiatric conditions that needed regular
medications and alcohol abuse. The co-morbidities were
diagnosed typically years before the HRQoL-measure
at study baseline, and thus could be considered as risk
factors of poor HRQoL. Although this suggests causality, it
cannot be confirmed in this cross-sectional study. The
present study cohort reflects the heterogeneity found in
COPD at large. The patients represented both genders
and all severity stages of airway obstruction, and various
patterns of co-morbidities were present, including car-
diovascular diseases, chronic atrial fibrillation, hyper-
tension, diabetes, obesity, psychiatric conditions, cancer,
and alcohol abuse, confirming previous reports on mul-
timorbidity in COPD [4,38].
Accumulation of comorbidities into the present COPD
cohort was less than in some previous reports. In the
present data set the diagnoses are based on retrospective
medical records, but COPD patients may go under diag-
nosed when the symptoms of co-existing disease are not
recognised or the symptoms are considered adverse events
of COPD medication. Underestimation of co-existing dis-
eases would thus weaken the role of co-morbidities explai-
ning the variability found in HRQoL. Two to three times
higher risk of cardiovascular diseases has been re-
ported in several COPD populations [38,39]. Incom-
patibilities in the diagnostic criteria and differences in
characteristics of COPD populations may explain to
some extent the inconsistencies between studies. Preventive
care for example in coronary disease has become morepared to those in an age and gender matched Finnish
Finnish population cohorts health 2000
N = 5000
Total % Total % Difference in prevalence
41 -
22 16 1.4 x
8 51 1.6 x
5 2 2.5 x
15 9 1.7 x
15 -
33 12 2.8 x
6 7 0.9 x
Table 4 Correlation matrix for lung function parameters, HRQoL, MRC Dyspnoea scale and age
15D score Age DLCOcVA FEV1% MRC scale FEV1*DLCOcVA AQ20 score
15D Score 1 0.01 0.11* 0.16*** −0.03 0.15** −0.69***
Age 0.01 1 −0.07 −0.19*** 0.02 −0.17** −0.09
DLCOcVA 0.11* −0.07 1 0.35*** 0.03 0.79*** −0.19***
FEV1% 0.16** −0.19*** 0.35*** 1 0.00 0.83*** −0.24***
MRC Scale −0.03 0.02 0.03 0.00 1 0.01 0.07
FEV1*DLCOcVA 0.15** −0.17** 0.79*** 0.83*** 0.01 1 −0.25***
AQ20 Score −0.69*** −0.09 −0.19*** −0.24*** 0.07 −0.25*** 1
*p-value < 0.05, **p < 0.01, ***p < 0.001.
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tients were at significant risk of lung cancer, heart fail-
ure, and death, but not at risk of myocardial infarction
[40]. In the present COPD cohort the diagnoses were
given by a specialist and gathered from medical records.
The diagnoses can be considered more plausible than
self-reported often used in previous reports. The preva-
lence may also reflect recruitment bias, i.e. if the most
seriously ill patients did not participate. Excessive alco-
hol consumption was pronounced among COPD pa-
tients. Compared to elderly Finns in general, alcohol
abuse was 4.5 fold more frequent among women and
2.3 fold more frequent among men with COPD [41]. Ex-
cess alcohol use has been found also in other COPD
populations [42]. Data on chronic atrial fibrillation and
diffusing capacity were not available for all, but the uni-
variate model suggested that chronic atrial fibrillation
would harm HRQoL (crude OR 2.4, 95% CI 1.00-6.0,
p ≤ 0.05), while impaired diffusing capacity did not.
Prevalence of hypertension (41%) and chronic atrial fib-
rillation (6%) were at the same level as in general age
and gender matched population in Finland [43].
Like in many previous studies, lung function alone was
not a strong predictor of either respiratory or general
HRQoL [22,44,45]. Literature on co-morbidities as de-
terminants of HRQoL in COPD is rather sparse. Using
St George’s Respiratory Questionnaire (SGRQ) in primary
health care COPD population (N = 1817) it has been shown
that patient with >3 co-morbidities had poorer HRQoL than
patients with 1–2 comorbidities [46]. In patients with <3
co-morbidities the generic instrument was more sensitive
than SGRQ suggesting that respiratory specific HRQoL is
not influenced by the presence of low levels of co-morbidity.
In another study (N = 326 COPD patients) the presence of
dyspnoea and exacerbation, depression was the most im-
portant contributor to HRQoL impairment measured by
SGRQ, whereas other comorbidities had only limited impact
[47]. When 23 co-morbid diseases were analysed in a
COPD cohort (N = 659, matching age and slightly more
advanced disease than in the present study), the presence
of three or more co-morbid diseases was more predictive
of HRQoL than any demographic variable or physiologicalmeasurement [45]. Insomnia, however, was the only separ-
ate disease that correlated to general HRQoL. In another
study by Putcha et al. (N = 843), four out of thirteen co-
morbid diseases (congestive heart failure, arthritis, diabetes,
incontinence/prostate disease) associated independently
with generic HRQoL [37]. All diagnostic information was
based on self-reported data and the severity of COPD was
not known in the latter study. These study designs in-
cluded depression, but no other psychiatric or any addict-
ive diseases like in our study. COPD patients in the
present study displayed a large scale of psychiatric symp-
toms from features of psychosis to rather mild anxiety or
depression. Not all of them had received a thorough psy-
chiatric evaluation and thus the exact nature of the disease
remained unknown, but the common nominator was the
use of regular psychiatric medication. Psychiatric condi-
tions (OR for low HRQoL for 15D 4.7 and for AQ20 2.0)
and alcohol abuse (OR for 15D 2.3 and for AQ20 3.0)
both had a strong impact on HRQoL that could be de-
tected by generic and respiratory specific instruments.
Our data also showed that diabetes affected generic
HRQoL (OR 2.1) while cardiovascular diseases showed a
similar trend even though not significant (OR 1.7). FEV1
was also a strong predictor of both generic and respiratory
specific HRQoL, however the effect was significant only at
late stages of disease (FEV1 < 40% of predicted).
Comparably with findings in the general population,
cardiovascular morbidity was more prevalent among men
than among women. Women reported significantly more
respiratory symptoms even though their FEV1 was slightly
better, as also reported earlier [48]. Regarding functional
inabilities, women more often had sleeping difficulties, de-
pression and distress while men suffered more often from
impaired sexual performance.
At present, there is some evidence that HRQoL has pre-
dictive value for risk of exacerbations, use of health care
resources, and mortality in COPD [49,50]. In the present
study generic HRQoL was statistically (p ≤ 0.001) and
clinically (MCID >0.03) poorer among patients who
died within the next five years. If the patients’ 15D score
was <0.815 his risk to die during the next five years was
2.3 times higher than among the rest of the patients
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associated with high mortality rate (OR = 2.16, p ≤
0.001). The clinical variables, which predicted both poor
HRQoL and mortality, were FEV1, alcohol abuse, and
cardiovascular diseases. HRQoL has been considered a
potential component to the new multidimensional
health status –measures in COPD [12]. Our results also
suggest that HRQoL might provide a broader insight in
predicting mortality than FEV1 alone.
Recent studies have shown clearly that COPD can no
longer be assessed as a disease only involving the lungs
[51]. Even though COPD has pulmonary and extra-
pulmonary manifestations both the generic and respira-
tory specific instruments gave surprisingly consistent
results. The most important risk factors for poor HRQoL
were identified by both instruments and by both analysis
approaches applied. The risk factors for increased
mortality were also partially overlapping and the HRQoL
score was per se correlated with mortality. We have pre-
viously shown that when multiple HRQoL measures over
five years are available for asthma and COPD patients
constantly declining trends can be recognized with high
probability [52]. In clinical practice the great benefit of
the generic HRQoL instrument is that it allows the com-
parison of treatment interventions not only among
COPD patients, but also in comparison to other patient
groups suffering chronic diseases. Effectiveness of
treatment options can be compared by using the ‘quality
adjusted life years’ (QALY) measurement. Further this
measurement allows us to consider the cost effectiveness
of the treatment e.g. how much the treatments option
costs per achieved QALY. It is an important additional
feature in HRQoL studies, since disease burden of COPD
is significant for public health care.Conclusion
Our results suggest that the effect of co-morbidities in
COPD is underestimated in regard of HRQoL. Psychiatric
conditions, alcohol abuse, cardiovascular disease and lung
function are comparably important in predicting the
HRQoL of a COPD patient. These findings are further
underlined by the higher prevalence of these conditions in
this hospital based COPD cohort, when compared to age
and gender matched general population. We chose for the
study two short and easy to fill-in questionnaires and thus
applicable also in clinical practice. The instruments have
been validated in COPD and they have been shown to
correlate to other more complex questionnaires. Being
generic, 15D better captured the impact of co-morbidities
while respiratory specific AQ20 was more sensitive to im-
paired lung function. Five-year mortality was significantly
higher in patients with poor HRQoL measure at study
baseline.Additional file
Additional file 1: Table S1. Dimensions of HRQoL determined by 15D
that differed significantly between males and females. Table S2
Dimensions of HRQoL determined by AQ20 that differed significantly
between males and females. Table S3 Risk factors for mortality among
COPD patients.
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